Study identifier:D8850R00001
ClinicalTrials.gov identifier:NCT05667116
EudraCT identifier:N/A
CTIS identifier:N/A
An Observational Study to Assess the Real-world Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among EVUSHELD-eligible Populations Receiving Care at UPMC in the United States
SARS-CoV-2, COVID-19
Phase 4
No
EVUSHELD
All
4232
Observational
12 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Oct 2023 by AstraZeneca
AstraZeneca
UPMC
No locations available
Arms | Assigned Interventions |
---|---|
EVUSHELD arm 3,000 Individuals given EVUSHELD for pre-exposure prophylaxis | Drug: EVUSHELD EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab) |
Concurrent Control arm 3,000 individuals eligible for EVUSHELD pre-exposure prophylaxis but did not receive Evusheld | - |